Satoh T, Cohen H T, Katz A I
Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois 60637.
J Clin Invest. 1993 Feb;91(2):409-15. doi: 10.1172/JCI116215.
We recently reported a novel intracellular mechanism of renal Na-K-ATPase regulation by agents that increase cell cAMP, which involves protein kinase A-phospholipase A2 and is mediated by one or more arachidonic acid metabolites (Satoh, T., H. T. Cohen, and A. I. Katz. 1992. J. Clin. Invest. 89:1496). The present studies were, therefore, designed to assess the role of eicosanoids in the modulation of Na-K-ATPase activity in the rat cortical collecting duct. The effect of various cAMP agonists (dopamine, fenoldopam, vasopressin, forskolin, and dibutyryl cAMP), which inhibited the pump to a similar extent (approximately 50%), was independent of altered Na entry as it was elicited in the presence of amiloride or nystatin, or when NaCl was replaced with choline Cl. This effect was completely blocked by SKF 525A or ethoxyresorufin, two inhibitors of the cytochrome P450-dependent monooxygenase pathway, or by pretreating the animals with CoCl2, which depletes cytochrome P450. Equimolar concentrations (10(-7) M) of the cyclooxygenase inhibitors indomethacin or meclofenamate caused only a partial inhibition of the cAMP agonists' effect on the pump, whereas nordihydroguaiaretic acid or A 63162, two inhibitors of the lipoxygenase pathway, were without effect. Furthermore, two products of this pathway, leukotriene B4 and leukotriene D4, had no effect on Na-K-ATPase activity, and ICI 198615, a leukotriene receptor antagonist, did not alter pump inhibition by cAMP agonists. Several P450 monoxygenase arachidonic acid metabolites (5,6-epoxyeicosatrienoic acid; 11,12-epoxyeicosatrienoic acid; 11,12-dihydroxyeicosatrienoic acid; and 12(R)-hydroxyeicosatetraenoic acid) as well as PGE2 inhibited the Na:K pump in dose-dependent manner, but the effect of PGE2 was blocked when Na availability was altered, whereas that of 12(R)-HETE remained unchanged. We conclude that the cytochrome P450-monooxygenase pathway of the arachidonic acid cascade plays a major role in the modulation of Na:K pump activity by eicosanoids in the rat cortical collecting duct, and that products of the cyclooxygenase pathway may contribute to pump inhibition indirectly, by decreasing intracellular Na.
我们最近报道了一种由增加细胞环磷酸腺苷(cAMP)的物质调控肾脏钠钾ATP酶的新型细胞内机制,该机制涉及蛋白激酶A - 磷脂酶A2,并由一种或多种花生四烯酸代谢产物介导(佐藤,T.,H. T. 科恩,和A. I. 卡茨。1992年。《临床研究杂志》89:1496)。因此,本研究旨在评估类花生酸在大鼠皮质集合管中对钠钾ATP酶活性调节中的作用。各种cAMP激动剂(多巴胺、非诺多泮、血管加压素、福斯可林和二丁酰cAMP)对泵的抑制程度相似(约50%),其作用与钠进入的改变无关,因为在存在阿米洛利或制霉菌素的情况下,或者当氯化钠被氯化胆碱替代时也会出现这种抑制作用。这种作用被细胞色素P450依赖性单加氧酶途径的两种抑制剂SKF 525A或乙氧基试卤灵完全阻断,或者通过用氯化钴预处理动物来耗尽细胞色素P450也可阻断。等摩尔浓度(10⁻⁷ M)的环氧化酶抑制剂吲哚美辛或甲氯芬那酸仅部分抑制cAMP激动剂对泵的作用,而脂氧合酶途径的两种抑制剂去甲二氢愈创木酸或A 63162则无作用。此外,该途径的两种产物白三烯B4和白三烯D4对钠钾ATP酶活性无影响,白三烯受体拮抗剂ICI 198615也不改变cAMP激动剂对泵的抑制作用。几种细胞色素P450单加氧酶花生四烯酸代谢产物(5,6 - 环氧二十碳三烯酸;11,12 -环氧二十碳三烯酸;11,12 -二羟基二十碳三烯酸;和12(R)-羟基二十碳四烯酸)以及前列腺素E2以剂量依赖性方式抑制钠钾泵,但当钠的可利用性改变时,前列腺素E2的作用被阻断,而12(R)-羟基二十碳四烯酸的作用保持不变。我们得出结论,花生四烯酸级联反应的细胞色素P450 -单加氧酶途径在大鼠皮质集合管中类花生酸对钠钾泵活性的调节中起主要作用,并且环氧化酶途径的产物可能通过降低细胞内钠间接导致泵的抑制。